MUC1 and adenocarcinoma: The present study demonstrated that patients with NSCLC, including both adenocarcinoma and squamous cell carcinoma, had a significant decrease in plasma IgG antibodies against the combination of three peptide antigens derived from CD25, MUC1, and VEGFR1, respectively.